Postoperative pain comprises one of the larger segments of the total market for acute pain therapies, and it has experienced substantial growth over the past decade due to the market uptake of Mallinckrodt’s Ofirmev and Pacira’s Exparel in the United States. Physicians generally rely on multimodal therapy, a method of layering drugs in different analgesic classes (e.g., an NSAID / acetaminophen and an opioid), to manage acute postoperative pain in an attempt to minimize side effects and reduce opioid consumption. Emerging therapies for postoperative pain will have to demonstrate convincing efficacy, safety, and convenience profiles to gain market share in this highly generic market, and market access will be challenging for emerging products unless a strong value proposition is made.
Geography: United States.
Primary Research: 6 interviews with thought-leading anesthesiologists and surgical specialists; supported by survey data.
Epidemiology: Surgical events resulting in postoperative pain.
Forecast: Branded drug-level sales in 2019; sales expectations for current brands and late-phase emerging therapies.
Emerging Therapies: Phase III/PR: 8 drugs.
Special Topics provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, unmet need and market opportunity, market access factors, in-depth pipeline assessments, and emerging drug sales expectations supported by detailed primary and secondary research.